Abstract: A novel growth factor, neurturin, is disclosed. The human and mouse amino acid sequences have been identified. Human and mouse neurturin genomic DNA sequences have been cloned and sequences and the respective cDNA sequences identified. The subcloning into vectors and the preparation of cells stably transformed with the vectors is also disclosed. In addition, methods for treating degenerative conditions using neurturin, methods for detecting gene alterations and methods for detecting and monitoring patient levels of neurturin are provided. Methods for identifying additional members of the neurturin-GDNF family of growth factors are also provided.

Abstract: The invention relates to a general process by which recombinantly derived variable domains of antibodies encompassing either or both light and heavy variable regions with or without respective constant regions are engineered and selected for identification of unique surface domains of pharmaceutical targets or parts thereof which regulate target function. The recombinant antibodies are useful as reagents for high volume, rapid screening of occupation of the active surface domains by natural or synthetic entities. This invention is also directed to elucidating the three dimensional conformation of the antibodies, or parts thereof, which bind to the pharmaceutical targets and confers activity. Methods for creating high resolution molecular models which can direct the synthesis of biologically active small organic molecules useful as viable discovery drug leads are also provided.

Abstract: A factor that indicates fertilization of an ovum before implantation, Preimplantation Factor (PIF), has been found. PIF also provides an early indication of pregnancy, malignancy, and autoimmune diseases. Assays for PIF are described. Detection of PIF in mammalian blood and other fluids is utilized in various diagnostic tests.

Abstract: A method of performing immunoassay to detect the level of target proteins common to various malignancies including metallopanstimulin or metallopanstimulin-like materials as well as complement components, in a biologic sample is provided wherein the protein molecules in the patient sample compete with radiolabeled peptide for sites on the Anti-peptide-specific antibody. The amount of radioactivity measured is inversely proportional to the concentration of protein molecules present in the patient sample, which is determined from a standard curve. Another method includes determining the presence of a protein elevated in the serum of patients with neoplasms by the detection of the interference of binding or precipitation of a first antibody by a second antibody by the target protein.

Abstract: The subject invention concerns the use of monoclonal antibody ANAF16C1 and Anaplasma species major surface protein-5 in the competitive inhibition format for the serological identification of animals infected with Anaplasma species.

Abstract: A novel polypeptide, designated neurotrophic factor-4 (NT-4), has been identified by PCR amplification of human genomic DNA. Provided herein is nucleic acid encoding NT-4 useful in diagnostics and in the recombinant preparation of NT-4. Also provided herein are nucleic acids encoding naturally occurring amino acid sequence variants of NT-4, designated NT-4.beta., NT-4.gamma., and NT-4.DELTA.. The neurotrophic factors of the invention are useful in the treatment of nerve cells and in diagnostic assays.

Abstract: The complete amino acid and nucleotide sequence for adenylate cyclase stimulating factor is provided, thereby facilitating the synthesis of ACSF in recombinant cell culture. ACSF amino acid sequence variants and ACSF antibodies are provided which are useful in the treatment of humoral hypercalcemia of malignancy or in immunoassays for ACSF. In particular, antibodies capable of binding only the C-terminal domains of ACSF are useful in immunoassays for ACSF which avoid interference by parathyroid hormone. Also provided are novel polypeptides selected from the group of the ACSF basic peptide, the ACSF C-terminal peptide, or the ACSF domain containing both of the basic and C-terminal peptides.

Abstract: Chimeric antibodies which bind to unique antigenic epitopes of IgE (designated ige.b1) which are present on IgE-bearing B lymphocytes but not basophils are described.

Abstract: The invention relates to a monoclonal antibody PC47H specifically recognizing fucosylceramide derived from a ceramide-mono-glycoside fraction of neutral glycolipid extracted and purified from human cancer tissues and having properties such as belonging to IgM and showing reactivity to neither of normal peripheral blood lymphocyte, normal erythrocyte, normal fibroblast nor cell lines derived from leukemia, hepatoma, breast cancer and neuroblastoma but to cell lines derived from lung cancer, stomach cancer, colon cancer and pancreas cancer; a hybridoma having ability to produce the aforementioned monoclonal antibody; a method for manufacturing the aforementioned monoclonal antibody which comprises immunizing an animal with a neutral glycolipid fraction extracted from human pancreas cancer, fusing animal cells with myeloma cells to generate hybridomas, cloning the hybridomas, selecting clones which produce monoclonal antibodies which specifically recognize fucosylceramide and then using the clones to manufacture

Abstract: A method for producing antibodies specific for antigenic associated with the extracellular segment of the domain which anchors immunoglobulins to the B cell membrane is disclosed. The epitopes recognized by the antibodies of the invention are present on IgE-bearing B cells but not basophils or in the secreted, soluble form of IgE.

Abstract: Monoclonal antibodies manifesting specific reactivity to benign adenomatous polyps of the human colon are produced. Hybridoma technology was utilized to produce immunoglobulin producing cell lines. Splenic lymphocytes from mice, immunized with a membrane fraction derived from human tubular adenomatous colonic polyps, were fused with a mouse non immunoglobulin secreting myeloma cell line (NS-1). Screening of hybridoma culture supernatant for positive reactivity with adenomatous colonic polyp extract, and negative activity with extracts from normal liver and spleen allowed for selection of desired immunoglobulin producing cultures. Further screening of expanded cultures with extracts of colorectal cancer, apparently normal mucosa adjacent to the cancer, and a variety of normal human extracts allowed further distinctions in binding reactivity. One such selected cell line produced a monoclonal antibody designated Adnab-9 selected on this basis.

Abstract: New hybridoma cell lines which synthesize highly specific monoclonal antibodies (mAb) against human tumor necrosis factor (TNF), monoclonal antibodies against TNF, a process for the preparation of such hybridoma cell lines and antibodies, and the use of the monoclonal antibodies are described.

Abstract: Antigenic epitopes associated with the extracellular segment of the domain which anchors immunoglobulins to the B cell membrane are disclosed. For IgE, the epitopes are present on IgE-bearing B cells but not basophils or the secreted, soluble form of IgE. DNA constructs encoding chimeric antibodies, with murine variable regions and human constant regions, which bind to this epitope, can be produced and expressed in transfected mycloma cells.

Abstract: The present invention provides a composition consisting of a monoclonal antibody that defines an epitope found on an antigen antigen/normal cross-reacting antigen produced by hybridoma XMMBR-B14 (HB 9308) conjugated to a detectable moiety, and a kit containing the antibody. Hybridoma XMMBR-B14 was deposited with the ATCC on Jan. 14, 1987 and given the ATCC Accession No. HB 9308.

Abstract: An immunometric assay is disclosed for biologically active tumor necrosis factor in a biological sample comprising, forming a complex of a first labeled monoclonal antibody, biologically active TNF, and a second monoclonal antibody which can be bound to an insoluble substrate and detecting the amount of label associated with the complex. The assay is characterized by employing first and second monoclonal antibodies which react with the same epitopic site on TNF-alpha monomer. A method is also disclosed for blocking accelerated TNF degradation in a non-preserved biological sample, such as blood, comprising contacting the biological sample with EDTA, luminol, or a combination thereof.

Abstract: This invention provides a monoclonal antibody which specifically forms a complex with amino acids 1-87 of PTHLP which does not form a complex with amino acids 1-34 of PTHLP, and which forms a complex with the epitope to which any of the monoclonal antibodies produced by the hybridomas 212-10.7, (ATCC Accession No. HB9930), 199-999 (ATCC Accession No. HB9929), 199-278 (ATCC Accession No. HB9931), is directed.This invention further provides methods of detecting PTHLP and of diagnosing and treating humoral hypercalcemia of malignancy.

Abstract: The present invention pertains to the SF-25 antigen of colon adenocarcinoma cells, to functional derivatives of this antigen, and to antibodies and antibody fragments capable of binding this antigen. The invention further discloses methods of diagnosing and treating colon cancer which employ the above molecules.

Abstract: A Ca.sup.2+ dependent monoclonal antibody that specifically binds to a specific twelve peptide sequence (E D Q V D P R L I D G K) in the activation region of the Protein C. The antibody does not bind to Activated Protein C and can be used to inhibit activation of Protein C by thrombin-thrombomodulin. The antibody can be isolated from cell culture or ascites fluid in large quantities by affinity chromatography with mild conditions using the peptide bound to an immobilized substrate. The antibody has a number of specific uses in isolation and characterization of Protein C and as a model for the design of Ca.sup.2+ dependent antibodies for the isolation of other proteins, as a diagnostic, and as a therapeutic to prevent activation of Protein C. The Protein C can be naturally produced or produced by expression of the recombinant gene. Advantages of the antibody in purification of Protein C include the specificity for Protein C and not Activated Protein C, and the unique Ca.sup.

Abstract: This invention is directed to the generation of hybridomas and the monocot-specific monoclonal antibodies prepared from those hybridomas against the acetohydroxyacid synthase enzyme. The monoclonal antibodies are useful to isolate and purify the enzyme. The invention is also directed to peptides corresponding to fragments of the enzyme which then are used to generate the monoclonal antibodies.

Abstract: The present invention relates to a monoclonal antibody MLS 102 recognizing human intestinal cancer cells, especially their sugar chain of glycoprotein, and more specifically NeuAc .alpha.2.fwdarw.6GalNAc. The invention also relates to a hybridoma producing the monoclonal antibody which is prepared by fusing splenic cells of a mouse immunized by human intestinal cancer cells with myeloma cells.